Free Subscription to Health Content Weekly Perspective
Categories
- Advertising
- Clinical tools
- Clinical Trials
- CMS, HHS
- Companies
- Conferences
- Consumer Health
- Databases
- DrugInfo
- EBM
- EHRs
- Google Health
- Health2.0
- Healthcare Publishing
- HealthIT
- HIE
- Image search
- ims health
- Infocommerce
- InfoCommerce Group
- IPO
- Licensing
- medical devices
- Medical Research
- Medical Search
- Medical Tourism
- Microsoft HealthVault
- multimedia
- Payers
- Personalized Medicine
- Pharma
- Physician directories
- Physicians
- Point-of-care Applications
- Social networking
- Uncategorized
- Verispan
Archives
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
Blogroll
Thomson Reuters Launches Niche Database for Pharma Industry
- Posted August 21st 2008
- by Marji
Thomson Reuters has launched BIOMARKERcenter, a biomarker intelligence resource for the pharmaceutical industry. It will enable users to assess the potential of biomarkers, which are measurable indicators that can be used to define a biological state.
BIOMARKERcenter covers the biomarkers identified in literature, patents, conferences, clinical trial information and other sources for all major therapeutic areas, such as oncology, cardiovascular diseases, diabetes, respiratory disorders, autoimmune diseases and neurological disorders. Each therapy are includes biomarkers with established clinical usage as well as emerging uses for biomarkers.
Each record is created by Thomson Reuters experts and it provides a unique report on the biomarker using a lifecycle model. Other data that users will be able to access includes the name, classification, biological entities/processes involved, associated drugs, role or utilities, measurement techniques, regulatory status and related diagnostic kits.
Thomson Reuters is making access to BIOMARKERcenter very easy for users through a variety of delivery methods: a standalone web solution, fully integrated into Prous Science’s Integrity platform, or as an XML feed to internal customer databases.
This is a very innovative idea for a couple of reasons. First of all, it addresses a niche that most likely hasn’t previously received a lot of attention from healthcare information providers. Instead of focusing on a broad pharmaceutical issue, Thomson Reuters has targeted a very specialized area that will attract a small, but loyal, audience.
Also, the database contains information that can strongly impact pharmaceutical companies’ bottom lines and provide them with a competitive advantage in the marketplace. This is very powerful content, and it should attract many new customers over time. Another strong selling point is the varied delivery methods in which users can access the database. This should, without question, assist in the rapid adoption of this new product offering.
Leave a Reply